About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
The author reviews the reasons for FDA labeling changes for estrogens and estrogen–progesterone combinations as hormonal therapy; sertraline for depression; and palivizumab as prophylactic therapy for respiratory infections.
Marvin M. Goldenberg, PhD, RPh, MS
The authors present the results of a survey sent to the directors of MCOs to ascertain their views on chronic pain in their patients.
Chureen Carter, PharmD, Neil I. Goldfarb, Christine W. Hartmann, MSS, Adam R. Roumm, Susan M. Vallow, MBA, MA, and Michael Durkin, MS
The first of the new selective cholesterol absorption inhibitors, ezetimibe has been approved for several indications.
Beata M. Domagala, PharmD, Michelle Leady, PharmD, and Daniel S. Streetman, PharmD
Now is the time to order vaccine for the fall flu season. The authors discuss the ways in which many diseases in older adults could be prevented with more effective immunization strategies.
S. Jay Weaver, PharmD, and Paul L. Doering, MS Pharm
David B. Nash, MD, MBA
P&T is now accessible on the World Wide Web. But wait, there’s more!
Matthew Grissinger discusses some key words that should be considered “red flags.”
The latest information about approvals, indication changes, industry updates, and news from the FDA.
Stephen Barlas ponders the tragic loss of life caused by a medical error.
Dr. Liang-Kim reviews the role of interferon beta-1a in multiple sclerosis.
Kathleen S. Liang-Kim, RPh